PRINCETON, N.J., Dec. 3, 2012 /PRNewswire/ -- Covance Inc. (NYSE: CVD), a leading provider of drug development services, today announced that the CEO Roundtable on Cancer accredited the company with the CEO Cancer Gold Standard™, recognizing the organization's extraordinary commitment to the health of its employees and their families.
The CEO Cancer Gold Standard is a series of cancer-related recommendations developed by the CEO Roundtable on Cancer, a non-profit organization of cancer-fighting CEOs whose mission is to make continual progress toward the elimination of cancer as a personal disease and public health problem.
To receive the CEO Cancer Gold Standard designation, Covance established programs to reduce cancer risk by prohibiting tobacco use at the workplace; encouraging physical activity; promoting healthy nutrition; detecting cancer at its earliest stages when outcomes may be more favorable; and providing access to quality care, including participation in cancer clinical trials.
"Our goal is to extend the attributes of the Gold Standard to many more lives," said Christopher A. Viehbacher, Chief Executive Officer of Sanofi and Chairman of the CEO Roundtable on Cancer. "I hope the leadership and commitment of Covance will encourage other employers to become Gold Standard accredited."
"In pursuit of our mission of bringing new medicines to the market, we have helped develop many life-saving cancer medicines," said Joe Herring, Covance Chairman and Chief Executive Officer. "As we continue to work for treatments and cures, we also understand that prevention is an important component in the battle against the disease. Encouraging employees and their families to stay as healthy as possible helps them live longer, more productive lives and helps us advance the important work we conduct on behalf of patients around the world. Together, we our doing our part to reduce the burden of cancer. Achieving the Gold Standard accreditation is an important milestone in our journey."
About The CEO Roundtable on Cancer
The CEO Roundtable on Cancer is a nonprofit organization of cancer-fighting CEOs who created the CEO Cancer Gold Standard in collaboration with the National Cancer Institute. The organization was founded in 2001, when former President George H.W. Bush challenged a group of executives to "do something bold and venturesome about cancer within your own corporate families." The CEOs responded by creating and encouraging the widespread adoption of the CEO Cancer Gold Standard, a comprehensive program designed to combat cancer from every angle by focusing on prevention, early detection and quality care. Today, more than 3 million employees and family members are benefiting from the vision and leadership of employers who have chosen to become Gold Standard accredited.
For more information on the CEO Cancer Gold Standard™ and the web-based accreditation process and support, please visit www.CancerGoldStandard.org.
Covance, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies, with annual revenues greater than $2 billion, global operations in more than 30 countries, and more than 11,000 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com.
Forward Looking Statements
Statements contained in this press release which are not historical facts, such as statements about prospective earnings, savings, revenue, operations, revenue, earnings growth, and other financial results are forward-looking statements pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All such forward-looking statements including the statements contained herein regarding anticipated trends in the Company's business are based largely on management's expectations and are subject to and qualified by risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. These risks and uncertainties include, without limitation, competitive factors, outsourcing trends in the pharmaceutical industry, levels of industry research and development spending, the Company's ability to continue to attract and retain qualified personnel, the fixed price nature of contracts or the loss or delay of large studies, risks associated with acquisitions and investments, the Company's ability to increase order volume, the pace of translation of orders into revenue in late-stage development services, testing mix and geographic mix of kit receipts in central laboratories, fluctuations in currency exchange rates, and other factors described in the Company's filings with the Securities and Exchange Commission including its Annual Report on Form 10-K and Quarterly Reports on Form 10-Q. The Company undertakes no duty to update any forward looking statement to conform the statement to actual results or changes in the Company's expectations.
SOURCE Covance Inc.
Melissa Thompson, +1-609-452-4082, Melissa.Thompson1@covance.com